2022 - RAS Dialogue Blog
-
KRASG12C inhibition drives anti-tumour immunity in lung cancer but combinations with anti-PD1 immunotherapy may only benefit patients with ‘inflamed’ tumoursUsing a novel immunogenic mouse model of KRAS-mutant lung cancer, the Downward lab asks the questions ‘what is the effect of KRAS G12C on the tumour microenvironment and on anti-tumour immunity?’ and ‘how well will anti-PD1 immunotherapy work in combination with KRAS G12C inhibitors?’
-
The use of Molecular Docking as a ligand discovery tool; Can machine learning help the pursuit for ligands?Molecular docking is a powerful computational tool used in drug discovery, and has been a valuable asset in the search for KRAS therapeutics. Will machine learning/AI drive it to new heights?
-
Could CryoEM structures of neurofibromin lead the way to better therapeutic approaches for Neurofibromatosis type 1?Several structures have been recently reported detailing the NF1 protein. Will these structures help researchers discover novel therapeutic approaches to neurofibromatosis type 1?
-
Top-Down Proteomics Reveals the KRAS Proteoform Landscape in Colorectal CancerMeasuring PTM differences across RAS isoforms and mutants is quite the challenge. Here, the authors discuss how they used top-down proteomics to uncover a diverse RAS proteoform landscape across cancer cell lines and tumor samples.
-
Sin1: a novel RAS effector with isoform specificitySin1, a member of the mTORC2 complex, is found to interact preferentially with KRAS4A via an atypical RAS binding domain. This interaction is shown to be dispensable for mTORC2 activity.